GYNAE - PIL - GYNAE - PIL is a man-made form of an amino acid (protein) called lysine. GYNAE - PIL prevents enzymes in the body from breaking down blood clots.
The Cyklokapron and Lysteda brands of GYNAE - PIL are used for different medical conditions.
Cyklokapron is used to prevent bleeding in people with hemophilia who need to have a tooth pulled. This medication is usually given just before the dental procedure, and daily for up to 8 days afterward.
Lysteda is used to treat heavy menstrual bleeding. This medication will not treat premenstrual syndrome (PMS).
GYNAE - PIL may also be used for purposes not listed in this medication guide.
Pharmacology: Inhibits fibrinolysis to stop bleeding.
Indication: For short-term use in patients with hemophilia to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction (injection only); treatment of cyclic heavy menstrual bleeding (oral only).
Unlabeled Uses
Treatment of GI hemorrhage, hereditary angioneurotic edema, primary or intrauterine device–induced menorrhagia, or recurrent epistaxis; prevention of perioperative bleeding or rebleeding after subarachnoid hemorrhage.
GYNAE - PIL is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. GYNAE - PIL is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. GYNAE - PIL is about 10 times more potent in vitro than aminocaproic acid. GYNAE - PIL binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. GYNAE - PIL in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by GYNAE - PIL may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).
Oral Short-term management of haemorrhage
Adult: 1-1.5 g or 15-25 mg/kg 2-4 times daily.
Child: 25 mg/kg bid or tid. Renal impairment: Adjust dose based on serum creatinine concentration: 120-250 micromol/l: 15 mg/kg bid daily; 250-500 micromol/l: 15 mg/kg once daily; >500 micromol/l: 7.5 mg/kg once daily or 15 mg/kg once every 48 hr. Oral Management of hereditary angioedema
Adult: 1-1.5 g bid or tid.
Child: 25 mg/kg bid or tid. Renal impairment: Adjust dose based on serum creatinine concentration: 120-250 micromol/l: 15 mg/kg bid daily; 250-500 micromol/l: 15 mg/kg once daily; >500 micromol/l: 7.5 mg/kg once daily or 15 mg/kg once every 48 hr. Intravenous Short-term management of haemorrhage
Adult: 0.5-1 g or 10 mg/kg tid or 25-50 mg/kg daily by continuous infusion.
Child: 10 mg/kg bid or tid. Renal impairment: Adjust dose based on the serum-creatinine concentration: 120-250 micromol/l: 10 mg/kg bid daily; 250-500 micromoles/l: 10 mg/kg once daily; >500 micromol/l: 5 mg/kg once daily or 10 mg/kg once every 48 hr. Incompatibility: Incompatible with benzylpenicillin.
GYNAE - PIL helps to prevent and reduce bleeding. It is used to control bleeding after certain surgical procedures, especially in people whose blood cannot clot properly or takes a longer time to clot. It may also be used to control bleeding in other situations, as decided by your doctor.
Indications:
Adult: PO Short-term management of haemorrhage 1-1.5 g 2-4 times/day. Long-term management of hereditary angioedema 1-1.5 g 2-3 times/day. IV Short-term management of haemorrhage 0.5-1 g 3 times/day.
Oral Short-term management of haemorrhage
Adult: 1-1.5 g or 15-25 mg/kg 2-4 times daily.
Child: 25 mg/kg bid or tid. Renal impairment: Adjust dose based on serum creatinine concentration: 120-250 micromol/l: 15 mg/kg bid daily; 250-500 micromol/l: 15 mg/kg once daily; >500 micromol/l: 7.5 mg/kg once daily or 15 mg/kg once every 48 hr. Oral Management of hereditary angioedema
Adult: 1-1.5 g bid or tid.
Child: 25 mg/kg bid or tid. Renal impairment: Adjust dose based on serum creatinine concentration: 120-250 micromol/l: 15 mg/kg bid daily; 250-500 micromol/l: 15 mg/kg once daily; >500 micromol/l: 7.5 mg/kg once daily or 15 mg/kg once every 48 hr. Intravenous Short-term management of haemorrhage
Adult: 0.5-1 g or 10 mg/kg tid or 25-50 mg/kg daily by continuous infusion.
Child: 10 mg/kg bid or tid. Renal impairment: Adjust dose based on the serum-creatinine concentration: 120-250 micromol/l: 10 mg/kg bid daily; 250-500 micromoles/l: 10 mg/kg once daily; >500 micromol/l: 5 mg/kg once daily or 10 mg/kg once every 48 hr. Special Populations: Renal impairment: Short-term management of haemorrhage: CrCl: >500 micromol/L: 12.5 mg/kg body wt once daily oral dose or 5 mg/kg IV once daily; 250-500 micromol/L: 25 mg/kg body wt bid oral dose or 10 mg IV once daily; 120-250 micromol/L: 25 mg/kg bid oral dose or 10 mg/kg body wt IV bid. Incompatibility: Incompatible with benzylpenicillin.
General and local bleeding or bleeding diseases. |
brands or generic drugs
